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1. Introduction 
The ligands which are used to label brain serotonin 
receptors in in vitro binding assays do not all bind to 
the same site; [3H]serotonin, for instance, is known 
to label serotonin-Sl binding sites [1 ] whose physiol- 
ogical relevance isunclear. In contrast, in the rat 
frontal cortex, [3H] spiperone was found to label 
serotonin receptors [2,3] which were called serotonin- 
$2 receptor sites [ 1 ]. The physiological role of the 
S2-receptors is better understood; they have been 
shown to mediate the antagonism of various ero- 
tonergic effects measured both in vitro and in vivo 
[ 1-4]. Recently, the serotonin-S2 receptors were 
obtained in a solubilized form by means oflysoleeithin 
[5]; the solubilized [3H]spiperone binding sites from 
the rat frontal cortex retained the high affinity prop- 
erties of the serotonin receptor in the original mem- 
brane [5,6]. However, this work was hindered by a 
high occurrence of non-specific binding. 
Since [SH] ketanserin, a new anti-serotonergic 
agent [7] was found to selectively label serotonin-S2 
receptors [4], we decided to re-examine the solubili- 
zation of serotonin receptors in rat as well as in dog 
brain using this ligand. 
(P) fraction was prepared as in [5]. This membrane 
preparation was treated at 0°C for 15 min with 0.25% 
lysolecithin (L-a-lysophosphatidylcholine, Sigma) 
suspended in 4 vol. 0.25 M sucrose containing 10 mM 
sodium phosphate buffer (pH 7.2), 1 mM EDTA and 
0.01% NAN3. After eentrifugation at 182 000 × g 
(ray) for 1 h, 0.4 ml aliquots of the supematant 
(which was taken as soluble extract) were incubated 
with 1 nM [3H]spiperone (53.4 Ci/mmol, NEN) or 
with 1 nM [3H]ketanserin (87.5 Ci/mmol, NEN) in 
the presence of various concentrations of unlabelled 
drugs, unless stated otherwise. After incubation 
(20 min at 30°C), the ligand-receptor complex was 
separated from the free ligand by means of a charcoal 
procedure [6,8]. An activated charcoal mixture 50 gl 
(10% charcoal and 2% BSA in water) were added to 
0.4 ml of the incubation medium and rapidly centri. 
fuged in a microfuge. 
Finally, 0.2 ml aliquots of the supematant were 
counted for radioactivity. Specific binding was 
defined as the difference between total binding and 
non-specific binding occurring in the presence of 
10 -6 M pipamperone. 
3. Results and discussion 
2. Materials and methods 
Mongrel dogs were anaesthetized with pentobarbital 
and Wistar rats were decapitated; their brains were 
removed and the frontal cortex was dissected out and 
then homogenized in 0.25 M sucrose. A microsomal 
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High non-specific binding represented a serious 
drawback when [3H]spiperone was used to label 
solubilized serotonin receptors [5]. This problem was 
partially solved by selectively preventing [3H] spiperone 
binding to the spirodecanone sites [5] or by changing 
the incubation conditions (30°C for 20 rain) and the 
assay procedure (charcoal method [6]). Therefore, 
we decided to use these optimal conditions in the 
present study with both [3H]ketanserin and [3H]- 
spiperone as ligands. 
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Fig.1. Inhibition of [ 3H] spiperone and [ 3H]ketanserin bind- 
ing in soluble xtracts from rat and dog frontal cortex. Both 
soluble xtracts were prepared by means of the same solubili- 
zation procedure (section 2). Incubation was performed at 
30"C for 20 min with 1 nM [3H]ligand and in the presence of 
various concentrations of pipamperone (PIP) or spiperone 
(SPIP). Non-specific binding ( - - - )  was defined by inhibi- 
tion at 10 -6 M pipamperone. 
Displacement curves of [3H]spiperone and [3H]- 
ketanserin binding were performed in soluble extracts 
of rat and dog. Fig.1 shows that spiperone and 
pipamperone (apotent serotonergic antagonist [3]) 
inhibited the binding of both [3H]ligands at nano- 
molar concentrations. However, more [3H] spiperone 
binding sites were displaced by unlabeUed spiperone 
than by pipamperone or ketanserin; the latter drugs 
showed the same plateau-value at maximal inhibition 
(not shown). In contrast, pipamperone and spiperone 
inhibited to the same extent [aH]ketanserin binding 
in solubilized extracts from rat or dog frontal cortex. 
These displaceable binding sites were not detectable 
in cerebeUar extracts. Moreover, in a control experi- 
ment, we found that unlabelled ketanserin and 
methysergide (a potent serotonergic antagonist lack- 
ing a~-adrenergic and Hl-histarninergic a tivities 
[7]) gave the same plateau.value asspiperone and 
pipamperone. The foregoing results clearly indicate 
that, in contrast o [3H]spiperone binding [5], 
chemical recognition sites of the ligand structure 
do not seem to be involved in [3H]ketanserin bind- 
ing. Furthermore, pipamperone (abutyrophenone 
derivative lacking the spirodecanone moiety and 
chemically distinct from ketanserin) can be considered 
as a safe compound for defining non-specific levels of 
[3H]ketanserin aswell as of [3H]spiperone binding. 
Table 1 reveals that, under identical experimental 
conditions, [aH]spiperone and [3H]ketanserin label 
nearly the same amount of specific binding sites in 
the rat frontal cortex extract. A greater proportion of 
specific binding was detected in the rat extract with 
[3H] ketanserin than with [3H]spiperone (fig.l). 
However, in the dog, there was less specific [3H]- 
ketanserin binding and relatively more non-specific 
binding. 
Using a soluble extract from rat frontal cortex 
[3H] ketanserin binding was saturable (fig.2) over the 
same range as membrane preparations [4]. Almost 
complete saturation was reached at 4 nM and under 
such conditions, the percentage of specific binding 
was still close to 50%. The Scatchard analysis provided 
a straight line suggesting the occurrence of a homog- 
eneous population of solubilized binding sites; similar 
characteristics have already been described when 
using [aH]spiperone [6]. K d and Bmax-ValUeS for 
[aH]ketanserin binding were of 1.9 nM and 1.3 pmol 
receptor sites/g tissue, respectively. This Kd.Value was 
very close to that reported for membrane prepara- 
tions (K d = 1.3 nM, measured in Tris-salt buffer [4]). 
At 30°C, the solubilized binding sites remained 
Table 1 
Comparison of [3H]spiperone and [3H]ketanserin binding in soluble extracts from rat 
and dog frontal cortex 
[ 3H] Ligand Animal Total binding Specific binding 
(1 nM) (fmol/ml extract) 
fmol/ml extract % Total binding 
[3H]Spiperone Rat 144.9 ± 0.8 78.4 ± 3.4 54 
[=H]Ketanserin Rat 130.0 ± 1.9 86.9 ± 3.2 67 
[3H]Ketanserin Dog 133.9 ± 7.4 57.4 ± 5.2 43 
Solubilization and incubation procedures were those in section 2. Specific binding was 
defined as the difference between the total binding and the binding obtained in the 
presence of 10-6 M pipamperone. The values presented are the mean of 3 independent 
determinations (± SD) 
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Fig.2. Concentration binding curves of [ SH ]ketanserin bind- 
ing in a soluble extract from rat frontal cortex. The assays 
were carried out for 20 min at 30°C with increasing concen- 
trations of [ 3H]ketanserin (0.11-7.02 nM) and the binding 
was measured by means of the charcoal technique. Specific 
binding (o - -e )  was defined as the difference between total 
(o - -o )  and non-specific binding (A___z~) occurring in the 
presence of 10 -~ M pipamperone. Inset: Scatchard plot of 
specific binding. 
stable for >/40 min [6]; the association rates of [3H]- 
spiperone [6] and [3H]ketansefin are relatively fast 
(tl/2"~ 1 min). 
Some differences were found between both ligands 
with regard to their dissociation properties. Fig.3 
shows that half the amount of  specific [3H]spiperone 
receptor complexes were dissociated after 2 min at 
30°C; as reported for membrane preparations [9], the 
dissociation curve did not follow a first-order eaction 
plot but apparently involved a rapid and a slow com- 
ponent. This problem was not encountered with [3H]- 
ketanserin in solubilized or membrane [4] prepara- 
tions from rat frontal cortex. Indeed, [3H]ketanserin 
was found to dissociate from the solubilized binding 
sites according to typical first-order kinetics. More- 
over, its dissociation rate (tl/2 = 7.5 min) was slower 
than that reported for [3H]spiperone. 
This observation added to the fact that the disso- 
ciation rate can be further reduced at low tempera- 
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Fig.3. Time curves for dissociation at 30"C of specific [SH]- 
spiperone (o - -o )  and [3Hlketanserin (o - -o )  binding in a 
soluble extract from rat frontal cortex. Dissociation is
presented as a first-order reaction plot of the release. [3H]- 
Ligands were used at 1 nM; after 20 rain at 30°C for reaching 
total association (specific binding values were 80 and 85 free1/ 
ml extract for [ SH] spiperone and [ s H]ketanserin binding, 
respectively), dissociation started by addition of 10 -6 M 
pipamperone. 
ture, enabled us to compare the solubilization yield 
of  ligand-free and of [3H] ketanserin.bound receptors. 
Table 2 shows that 10-times more specific [SH]- 
ketanserin binding sites were measured in the soluble 
extract when the membrane-bound receptors were 
labelled by [SH]ketanserin before solubilization. 
About 40% of the membrane-bound receptors were 
solubilized by lysolecithin as the [3H] ketanserin 
receptor complex, whilst only 4% of the original 
receptors were still detectable in the soluble prepara- 
tions under post-labelling conditions. The pre-labelled 
then solubllized [3H]ketanserin-receptor c mplexes 
were found to specifically dissociate when an excess 
of methysergide (10 -6 M) was added to the soluble 
extract. Therefore, [3H] ketanserin binding to the 
solubilized receptor sites retains the reversibility 
property even after the pre-labeUing procedure. 
Furthermore, comparison of  the solubilization yields 
in both pre- and post-labelling conditions allows a 
distinction to be made between extracted receptors 
which are accessible to, or inaccessible to, the ligand. 
This may be due to the presence of inhibitors which 
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Table 2 
Solubilization of specific [3H]ketanserin binding sites under pre- and postqabelling conditions 
Specific [3H]ketanserin binding (fmol/mg protein) Solubilization Recovery (%) 
yield (%) 
Starting Soluble Remaining Specific Proteins 
membranes extract pellet binding 
Preqabelling 
washed membranes 192.1 172.9 45.8 39.2 51.5 95.1 
Post-labelling 
unwashed membranes 235.8 18.0 75.0 4.0 18.6 98.9 
washed membranes 190.0 16.1 36.6 3.4 15.3 101.7 
Microsomal membranes (P-fraction) were prepared from rat cortex. Pre-labelling conditions: P-fraction (1/20, tissue wt/vol.) was 
incubated inphosphate buffer (10 mM NaH~PO4, 0.01% NAN3, pH 7.2) for 15 min at 37°C with 10 -3 M [3H]ketanserin in 
presence or absence of 10 -6 M methysergide. After cooling, the incubation medium was centrifuged at178 000 × g (ray) for 
45 min at 4°C. The resulting pellets (washed membranes) were suspended in2 vol. ice-cold water and immediately submitted to 
the solubilization procedure described in Methods. Post-labelling conditions: Washed and unwashed microsomal membranes were 
first treated with lysoleeithin (section 2). The supernatant (soluble xtract) and the remaining pellet obtained after centrifugation 
at 182 000 X g (rav) for 1 h were then incubated with 10 -9 M [3H]ketanserin (section 2) or with 10 -s M [3H]ketanserin (see pre- 
labelling conditions) in presence or absence of 10 -6 M methysergide, r spectively. Specific binding was def'med as the difference 
between total binding and non-specific binding occurring in the presence of 10 -6 M methysergide. At each step of both experi- 
mental procedures, [3H]ketanserin binding was immediately measured by Filtration on GF/B f'flters (membrane preparation) orby 
the charcoal method (solubilized extract) 
would become unmasked by the detergent treatment. 
Another possibility is that some receptor subunits 
dissociate during solubilization; this phenomenon could 
be prevented by labelling the receptor prior to its 
extraction. 
In the soluble extract from rat frontal cortex, 
there was a good correlation (table 3) between the 
ICso-Values of various compounds for [3H]spiperone 
and [3H]ketanserin binding; serotonin antagonists 
revealed a much higher potency than dopamine 
antagonists or agonists and an al-antagonist. In addi- 
tion, these 1Cso-values were in good agreement with 
those determined for [3H]spiperone [3] and [3H]- 
ketanserin [4] binding to S2-receptors in membrane 
Table 3 
Inhibitory potencies of various compounds for specific [3H ] spiperone and 
[aH~ketanserin b ding in soluble xtracts from rat and dog frontal cortex 
1C5o" (nM) 
[ 3H ] Spiperone [ 3 H ] Ketanserin 
Rat 
Rat Dog 
Ketanserin 10 7.9 4.2 
Spiperone 6.3 6.3 7.3 
Pipamperone 11.8 15.3 7.5 
Methysergide 25.1 18.1 10 
(+)-Butaclamol 316 331 178 
2-(N,N-dipropyl) 
Amino-5,6-dihy- 
droxytetralin 158 000 44 700 19 900 
Prazosin >10 000 105 000 28 900 
Solubilization and incubation conditions for [ 3H]ketanserin binding (1 nM) were 
described in section 2. ICs0-values for [3H]spiperone binding (1 nM) were from 
[5,61 
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preparations. The apparent affiuities of these com- 
pounds for [all] ketanserin binding were similar in 
soluble extracts from rat or dog frontal cortex, 
although a slight increase in the inhibitory potencies 
of these drugs was observed in dog extracts. 
The foregoing results provide vidence that the 
binding sites labelled by [3H]ketanserin in soluble 
extracts from rat and dog frontal cortex are sero- 
tonergic, thus confirming our data with [3H] spiperone 
[5]. However, since spiperone labels also dopamine 
receptors in lysolecithin extracts from rat striatum 
[6], the use of ketanserin certainly allows more 
accurate determinations of solubilized serotonin 
receptors in brain regions rich in dopamine receptors. 
Moreover, this ligand does not seem to label chemical 
recognition sites of ketanserin structure as spiperone 
did for spirodecanone sites. Under certain conditions, 
these non-specific binding sites could totally mask 
specific [3H]spiperone binding sites [5,10]. 
This study demonstrates that [3H]ketanserin 
specifically labels serotonin receptors in solubilized 
extracts from rat and dog frontal cortex. The main 
advantages of ketanserin when compared to spiperone 
are: its higher selectivity towards erotonin-S2 
receptors, its lower non-specific binding and its slower 
dissociation which follows a first-order kinetics. The 
latter property is probably essential to get a 40% 
solubilization yield in receptors which were labelled 
with [3H]ketanserin before their extraction. In the 
rat frontal cortex, [SH]ketanserin a d [SH]spiperone 
label an identical and homogenous population of 
solubilized serotonin receptors. 
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